

The Yeast C-Type Cyclin Ctk2p Is Phosphorylated and Rapidly Degraded by the Ubiquitin-Proteasome Pathway

GUILLAUME HAUTBERGUE† AND VALÉRIE GOGUEL*

Laboratoire de Génétique Moléculaire, Ecole Normale Supérieure, 75230 Paris, France

Received 18 August 1998/Returned for modification 5 October 1998/Accepted 16 December 1998

The yeast CTDK-I complex has been implicated in phosphorylation of the carboxy-terminal domain of the RNA polymerase II and in transcription control. It is composed of three polypeptides: Ctk1p and Ctk2p, a cyclin-dependent kinase and a C-type cyclin subunit, respectively; and Ctk3p, a third subunit of unknown function. Cyclins are regulatory proteins whose expression is tightly controlled at the protein level. In this study, we examined the regulation of Ctk2p expression in vivo. Surprisingly, unlike what has been described for cell cycle cyclins, steady-state levels of Ctk2p are composed of two relatively abundant forms, one of them phosphorylated. We show that this phosphorylated form is extremely unstable (half-life, 5 min) and that rapid proteolysis of Ctk2p exhibits growth-related regulation. Furthermore, our data establish that similar to the case for other naturally short-lived proteins, Ctk2p degradation is mediated by the ubiquitin-proteasome pathway. This is the first demonstration that a C-type cyclin is phosphorylated and targeted to the proteasome. Strikingly, neither phosphorylation nor destruction of Ctk2p requires its associated kinase Ctk1p, a feature fundamentally different from that which has been observed for cell cycle cyclins.

Cyclin-dependent protein kinases (CDKs) were first identified as central regulators of the major transitions of the eukaryotic cell division cycle. Their activity is determined by cyclin binding, by both positive and negative regulatory phosphorylation, and by polypeptide CDK inhibitors (40, 41). A single cyclin-dependent kinase subunit associates sequentially with multiple cyclin partners whose abundance fluctuates during the cell cycle (43). Indeed, one aspect of CDK regulation is triggered by the rapid destruction of their cyclin partners (23). Several studies both in yeast and in mammals have demonstrated that cyclins are selectively degraded by the ubiquitin-dependent proteasome pathway (9, 16, 53, 67). Substrates are first marked for degradation by conjugation with several molecules of ubiquitin, a highly conserved 76-amino-acid-long polypeptide that is joined reversibly by a covalent linkage. Usually, ubiquitin molecules are linked tandemly at lysine 48 to form multiubiquitin chains on substrate proteins (47). The resulting ubiquitin chains are in a dynamic state, subject to either further rounds of ubiquitination, ubiquitin removal by deubiquitinating enzymes, or degradation by the 26S proteasome (20). The 26S proteasome is a nuclear and cytosolic multicatalytic proteinase that breaks down targeted substrates to short peptides and recycles the ubiquitin molecules (18).

How proteins are targeted to the ubiquitin-mediated proteasome degradation pathway is not well understood. At least two motifs, which are also found in other ubiquitinated proteins, are necessary for cell cycle cyclin targeting to the ubiquitin proteolytic pathway. In the yeast *Saccharomyces cerevisiae*, mitotic (Clb1 to Clb4) and S-phase (Clb5 and Clb6) cyclins are targeted by a consensus sequence called the destruction box (16, 24, 42), while targeting of G₁ cyclins (Cln1 to Cln3) requires a carboxy-terminal PEST-rich region (49, 51). Regulation of cyclin destruction has also been shown to be

dependent on their associated CDKs (7), and several studies indicated that G₁ cyclin phosphorylation provides a signal that is necessary for their rapid degradation, suggesting that the relevant aspect of PEST sequences might be their richness in CDK phosphorylation target sites rather than their PEST amino acids per se. Indeed, mutations in the Cdc28p kinase consensus phosphorylation sites of G₁ cyclins resulted in their stabilization (28, 68). In summary, phosphorylation of cyclin PEST regions by their associating CDKs triggers their degradation. Thus, expression of a cyclin may be negatively regulated by the same cell cycle machinery that it activates.

C-type cyclins were originally identified in *Drosophila melanogaster* and humans because they could rescue G₁ cyclin function in yeast (33, 34). Since then, cyclins with significant homology to the cyclin box region of cyclin C have also been found in *Schizosaccharomyces pombe* (14, 39). Except for a recent study carried out in murine cells (36), there has been no evidence supporting a critical role for C-type cyclins in cell cycle progression. Rather, C-type cyclins seem to activate CDKs involved in the regulation of RNA polymerase II transcription. Unlike cell cycle cyclins, their expression does not fluctuate during the cell cycle (6, 39). The *S. cerevisiae* genome encodes three C-type cyclins that have been identified as subunits of RNA polymerase II carboxy-terminal domain (CTD) kinases. The RNA polymerase II CTD plays an essential role in mRNA synthesis, and its phosphorylation is a key feature of its function (8). The first CTD kinase, Kin28p, is associated with Ccl1p, a C-type cyclin, and with a third factor, Rig2p (12, 61, 62). This complex, like its human counterpart the Cdk7p kinase complex (37), is a component of the general transcription factor TFIIF (44, 58). Kin28p kinase activity is essential, as it is required for basal transcription (62). The second CDK implicated in CTD phosphorylation is the Srb10p/Ume5p/Ssn3p kinase and its cyclin partner Srb11p/Ume3p/Ssn8p, a kinase pair that is a component of the holoenzyme (35). The Srb10/11 complex is structurally related to mammalian Cdk8p kinase and its associated cyclin C (59). It was first characterized as a regulator of meiosis-specific genes in response to glucose (57). Since then, several studies established that Srb10/11 kinase is implicated in transcription repression of sets of genes

* Corresponding author. Present address: Service de Biochimie et de Génétique Moléculaire, CEA/SACLAY, F-91191 Gif sur Yvette, France. Phone: 33 1 69 08 84 17. Fax: 33 1 69 08 47 12. E-mail: goguel@jonas.saclay.cea.fr.

† Present address: Service de Biochimie et de Génétique Moléculaire, CEA/SACLAY, F-91191 Gif sur Yvette, France.

(1, 27, 65). Cooper et al. (6) showed that Ume3p cyclin is destroyed during meiosis and when cultures are subjected to heat shock. Mutational analysis identified several regions implicated in Ume3p stability: a PEST-rich region, a destruction box-like motif (RXXL), and the highly conserved cyclin box. Strikingly, this process does not appear to be affected in mutants defective for ubiquitin-mediated protein destruction. Furthermore, in contrast to what has been described for yeast cell cycle cyclins, the CDK activated by Ume3p is not required for the rapid degradation of this cyclin.

The third yeast C-type cyclin is a component of the CTDK-I complex, which was isolated in vitro by its ability to phosphorylate CTD-containing fusion proteins (29). It is composed of three subunits: the *CTK1* and *CTK2* genes encode a kinase and a C-type cyclin, respectively; the third subunit, Ctk3p, shows no similarity to other known proteins (30, 56). Deletion of any of the *CTK* genes generates cryosensitive cells. CTDK-I is related to the Srb10/11 kinase complex, although it seems to display a distinct role in transcriptional control (26). In vitro studies carried out with HeLa nuclear extracts have shown that CTDK-I can modulate the elongation efficiency of RNA polymerase II (31). In humans, the closest kinase to Ctk1p is Cdk9p, a CTD kinase that was first described as a positive transcription elongation factor (38). A recent study showed that Cdk9p is associated with a C-type cyclin that also interacts specifically with the human immunodeficiency virus type 1 transactivator protein Tat, which acts to enhance the processing efficiency of RNA polymerase II (66, 69). This finding led the authors to propose that this cyclin might be the TAR RNA-binding cofactor for Tat (66).

C-type cyclins constitute a divergent family of cyclins that display a prime role in RNA polymerase II transcription. Regulation of their expression is poorly documented. The yeast cyclin Ume3p is highly unstable under certain conditions, but how this regulation is achieved remains unknown. To try to understand the regulation of their expression, which probably exhibits specific features, we have studied the expression of Ctk2p, the CTDK-I C-type cyclin subunit. We show that at steady state under standard exponential growth conditions, Ctk2p comprises two forms, one a phosphorylated form that is very unstable. Our data establish that rapid proteolysis of Ctk2p is mediated by the ubiquitin-proteasome pathway. Strikingly, neither phosphorylation nor degradation of Ctk2p requires its activated kinase.

MATERIALS AND METHODS

Yeast strains and growth conditions. The yeast strains used in this study were WCG4a (*MAT α ura3 leu2-3,112 his3-11,15*) and its isogenic *pre1-1 pre2-2* derivative WCG4-11/22a, constructed by Richter-Ruoff et al. (48), and MHY501 (*MAT α his3- Δ 200 leu2-3,112 ura3-52 lys2-801 trp1-1*) and its isogenic *Δ doa4* derivative MHY623, described by Papa and Hochstrasser (45). The *Δ ctk* strains were derived from W303-1B (*MAT α ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura 3-1*). Null mutations were obtained by one-step gene replacement (50) by transformation with PCR fragments of the *TRP1* gene, using long oligonucleotides containing 5' and 3' sequences of each *CTK* gene.

Yeast cultures were grown at 30°C in SD (minimal) medium containing 0.67% yeast nitrogen base without amino acids (Difco) supplemented with appropriate nutrients for auxotrophy, plus 2% glucose as a carbon source. For induction of *CUP1* promoter-dependent ubiquitin alleles, CuSO₄ was added either at 0.2 mM for 5 h or at 0.1 mM overnight. For plasmid loss tests, transformants were grown in YPD (rich) medium (1% yeast extract, 1% Bacto Peptone, 2% glucose) for several generations. Culture dilutions were plated onto nonselective medium prior to replica plating onto selective medium. Yeast colonies unable to grow were scored. Yeast transformations were performed by the LiCl method (22).

Plasmids. *CTK1* and *CTK3* genes were obtained as *Bam*HI fragments (2,240 and 1,560 bp, respectively) by PCR on genomic DNA. The *CTK2* gene was carried into a *Bgl*II cosmid fragment (1,970 bp). To verify the disrupted strains, each gene was cloned into a *URA3* CEN plasmid. For overexpression experiments, each gene was cloned on a *URA3* 2 μ m plasmid. The epitope-tagged *CTK2* gene was constructed via several cloning steps. First, a PCR *Bam*HI fragment

containing the *CTK2* open reading frame was inserted into the *Bam*HI site of plasmid TL38 (*LEU2* 2 μ m) (4). The resulting construct, TL38-CTK2, allowed the expression of a Ctk2p protein fused to two influenza virus hemagglutinin (HA) epitope tags at its N terminus, under the control of the *PGK* promoter. Second, *CTK2* promoter sequences were cloned into pFL38 (*URA3* CEN) (3) by insertion of a 940-bp *Bam*HI-*Nco*I/*Sal*I PCR fragment into the *Bam*HI and *Sal*I sites of the vector, yielding pFL38-PrCTK2. Third, the tagged *CTK2* open reading frame was cloned under the control of the *CTK2* promoter by insertion of the TL38-CTK2 *Nco*I-*Xho*I fragment into the *Nco*I and *Xho*I sites of pFL38-PrCTK2. The final construct, CTK2-HA (*URA3* CEN), allows expression of a tagged Ctk2p under the control of its own promoter. Plasmid YEp96 (*TRP1* 2 μ m Ub) (10) contains a synthetic yeast wild-type ubiquitin gene under the control of the copper-inducible *CUP1* promoter. YEp105 (*TRP1* 2 μ m Myc-Ub) and YEp110 (*TRP1* 2 μ m UbK48R) are identical to YEp96, except that they encode a c-Myc-tagged ubiquitin (11) and a mutant ubiquitin with an arginine instead of lysine at amino acid position 48, respectively (21).

Yeast cell extracts and Western immunoblotting. Cells were grown to an optical density at 600 nm (OD₆₀₀) of 0.8 or 3. When indicated, cycloheximide (10 μ g/ml; Sigma) was added, and aliquots were frozen after different times of incubation. Cells (10 OD₆₀₀ units) were resuspended in 100 μ l of ice-cold tri-chloroacetic acid (TCA) buffer (20 mM Tris-HCl [pH 8], 50 mM ammonium acetate, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride [PMSF]). Cell suspensions were transferred to microfuge tubes containing 100 μ l of glass beads (425 to 600 μ m in diameter; Sigma) and 100 μ l of ice-cold 20% TCA. Cells were disrupted by vigorous vortexing (four times for 1 min each) with 1 min on ice between each vortexing. The beads were washed with 500 μ l of an ice-cold 1:1 mixture of 20% TCA and TCA buffer and vortexing twice for 1 min each time. Resulting extracts were centrifuged for 20 min at 4°C at 15,000 rpm, and pellets were resuspended in 100 μ l of TCA-Laemmli loading buffer (120 mM Tris base, 3.5% sodium dodecyl sulfate [SDS], 8 mM EDTA, 5% β -mercaptoethanol, 1 mM PMSF, 15% glycerol, 0.01% bromophenol blue). Samples were boiled for 10 min and centrifuged at 15,000 rpm for 10 min. Supernatants were collected, and 10- μ l aliquots were immediately loaded on an SDS-13% polyacrylamide gel (acrylamide-bisacrylamide, 33.5:0.3) for polyacrylamide gel electrophoresis (PAGE).

Immunoprecipitation experiments were performed essentially as described in reference 55. Cells were grown to an OD₆₀₀ of 0.8 or 3 as indicated, and extracts were made from 12 OD₆₀₀ units. Polyclonal rabbit antibody HA.11 (Babco) was added at 1/125 to the resulting extracts for 1 h at 4°C; 40 μ l of 50% protein G immobilized on Sepharose beads (Pharmacia Biotech) was mixed into the samples for 1 h at 4°C. The beads were washed three times with 0.5 ml of extraction buffer without PMSF and Complete protease inhibitor cocktail (Boehringer). Immunoprecipitated proteins were separated by SDS-PAGE as described above.

Proteins were electrotransferred onto nitrocellulose membranes (0.2- μ m pore size; Schleicher & Schuell). The membranes were hybridized with HA-specific monoclonal antibody 16B12 or Myc-specific monoclonal antibody 9E10 (Babco) at 1/5,000. After washing, membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (Promega). The blots were visualized by enhanced chemiluminescence (Amersham). Ctk2p half-lives in the *Δ ctk2* strain were quantified with a Luminescence Imager (Boehringer).

Phosphatase analyses. Cells (10 OD₆₀₀ units) were broken with 10% TCA as described above. After centrifugation, pellets were resuspended in 100 μ l of 50 mM Tris-HCl (pH 7.5)-2% SDS and cleared by centrifugation. Aliquots of 20 μ l were incubated with 2 U of alkaline phosphatase (calf intestinal phosphatase; Pharmacia Biotech) in a final volume of 750 μ l of 50 mM Tris-HCl (pH 7.5)-1 mM MgCl₂ at 37°C. When indicated, phosphatase inhibitors (100 mM Na₂HPO₄-NaH₂PO₄ [pH 7.5], 10 mM EDTA) were added. Proteins were precipitated for 15 min on ice with 750 μ l of cold 50% TCA. After centrifugation, pellets were resuspended in 15 μ l of TCA-Laemmli loading buffer with heating at 100°C for 10 min. Samples of 10 μ l were loaded on an SDS-13% polyacrylamide gel and Western immunoblotted as described above.

RESULTS

Overexpression of Ctk2p cyclin is toxic. The *S. cerevisiae* CTDK-I complex is encoded by three genes: *CTK1*, encoding a CDK subunit; *CTK2*, encoding a C-type cyclin subunit; and *CTK3*, encoding a subunit of unknown function. Disruption of any of these genes generates viable cells that display similar growth defects and are unable to grow at low temperatures (56). Cell cycle cyclins expression is tightly regulated at the level of both transcription and protein stability (43). As a consequence, overexpression of cell cycle cyclins usually generates growth defects (9, 60, 68). The CTDK-I complex is implicated not in cell cycle regulation but rather in transcription regulation (26, 31). Similarly to what has been observed for other C-type cyclins implicated in transcription control, *CTK2* mRNA levels do not fluctuate during the cell cycle (data not shown). However, because Ctk2p belongs to the cyclin

TABLE 1. Ctk2p overexpression from a multicopy plasmid affects wild-type cell growth

Plasmid	Doubling time		% Plasmid loss (30°C)
	30°C	15°C	
2 μ m control	2 h 35 min	8 h 30 min	35
2 μ m/CTK1	2 h 40 min	9 h 10 min	25
2 μ m/CTK2	4 h 50 min	15 h	>99
2 μ m/CTK3	2 h 25 min	8 h 25 min	26

family of proteins, its expression was also expected to be highly regulated. We therefore wanted to know whether its overexpression would generate growth defects. Each protein of the CTDK-I complex was overexpressed by introducing into wild-type cells multicopy plasmids carrying each coding sequence under the control of its cognate promoter. Growth rates were measured for cells grown in minimal medium at 30 and at 15°C (Table 1). Under both conditions, growth rates observed for cells overexpressing either Ctk1p or Ctk3p were identical to that observed for cells carrying a control plasmid, whereas cells overexpressing the Ctk2p cyclin showed significantly slower growth (Table 1). To confirm that overexpression of Ctk2p during exponential growth was toxic for the cells, plasmid loss was quantified. Strains were grown in rich medium for several generations prior to testing for plasmid retention. Whereas similar loss rates were obtained for cells carrying either a plasmid control or cells overexpressing Ctk1p or Ctk3p, cells overexpressing Ctk2p showed a much higher plasmid loss rate (Table 1). Taken together, these results show that overexpressing the C-type cyclin Ctk2p is toxic for the cells. This effect is consistent with a potential tight control of the Ctk2 cyclin C protein expression.

Ctk2p is phosphorylated in vivo. To study Ctk2p expression, its coding sequence was cloned on a single-copy plasmid under the control of the *CTK2* promoter sequences. The protein was fused at its N-terminal extremity to influenza virus HA epitope tags. The resulting construct, CTK2-HA, allowed expression of a functional protein because it could restore Δ ctk2 cell growth at the nonpermissive temperature (data not shown). Western blot analyses permitted detection of two specific bands corresponding to the expected size for Ctk2p (p38), the upper band being present at lower quantities (Fig. 1A). In an attempt to identify these two forms, extracts were treated with alkaline phosphatase (Fig. 1B). Treatment of extracts with alkaline phosphatase in the absence, but not in the presence, of phosphatase inhibitors resulted in the loss of the species with lower




FIG. 1. Ctk2p phosphorylation in vivo. Cells were grown in SD medium to an OD_{600} of 0.8. (A) Extracts from Δ ctk2 strain transformed with a plasmid control (T-) or with the CTK2-HA construct (T+) were analyzed by Western immunoblotting. Arrows indicate bands corresponding to Ctk2p. (B) Extracts from the Δ ctk2 strain transformed with the CTK2-HA construct were incubated for different times (minutes) at 37°C in phosphatase buffer with 2 U of alkaline phosphatase in the absence or presence (+I) of phosphatase inhibitors. In all figures, asterisks mark a nonspecific band which remained stable during all experiments, showing that all lanes were equally loaded.




FIG. 2. Ctk2p turnover in early exponential cells. Δ ctk2 cells transformed with the CTK2-HA construct were grown in SD medium to an OD_{600} of 0.8. Aliquots were taken at different times (minutes) of incubation at 30°C after the addition of cycloheximide. Resulting cellular extracts were analyzed by Western immunoblotting. After the addition of cycloheximide, Ctk2p levels were monitored for 180 min (A) and 5 min (B) to analyze turnover of the nonphosphorylated and phosphorylated species, respectively.

mobility. This loss was concomitant with an increase in the levels of the higher-mobility species, showing that it was due to serine and/or threonine dephosphorylation. In early exponentially growing cells, at steady state, Ctk2p occurs as two forms, one corresponding to a phosphorylated form (hereafter called Ctk2p-P).

Ctk2p is unstable. Protein stability is known to play an important role in regulation (19). In yeast, G_1 and mitotic cyclins as well as CDK inhibitors have been shown to be very unstable (23). Cyclin abundance is often rate limiting for CDK activity, and control of cyclin degradation rate is important in regulating cell cycle transitions. Examination of the yeast C-type cyclin Ume3p regulation showed that this cyclin is subjected to rapid destruction (6). To study Ctk2p stability, cycloheximide, an inhibitor of cytoplasmic translation, was added to cultures grown at 30°C in SD medium. Ctk2p levels were monitored by immunodetection. The lower band corresponding to the nonphosphorylated form of the cyclin was relatively unstable (half-life, 60 min; Fig. 2A). Furthermore, the upper band corresponding to the phosphorylated form was highly unstable, as we could not detect it 10 min after cycloheximide addition (Fig. 2A). To get a better insight into Ctk2p-P turnover, its levels were followed just after cycloheximide addition (Fig. 2B). Only 5 min after blocking protein synthesis, we could detect half of the initial levels of Ctk2p-P (half-life, 5 min; Fig. 2B). The same experiments conducted with a Myc-tagged Ctk2p protein generated identical results (data not shown). We conclude that Ctk2p is unstable in exponentially growing cells.

Ctk2p turnover exhibits growth-related regulation. A recent study showed growth-related changes in phosphorylation of the yeast RNA polymerase II CTD (46). Also, Cooper et al. (6) reported that Ume3p turnover is dependent on environmental changes. For these reasons, we examined Ctk2p expression in cells grown under different conditions. Extracts were made from late exponentially growing cells ($OD_{600} = 3$). Western blot analyses permitted detection of only one band whose migration corresponded to that of the nonphosphorylated form (Fig. 3). Ctk2p stability was determined after cycloheximide addition. In contrast to our previous observations made from cells grown to an OD_{600} of 0.8, Ctk2p levels did not vary for 4 h after inhibition of protein synthesis. This result shows that in late exponentially growing cells, Ctk2p turnover is dra-




FIG. 3. Ctk2p turnover in late exponential cells. Δ *ctk2* cells transformed with the CTK2-HA construct were grown in SD medium to an OD_{600} of 3. Aliquots were taken at different times (minutes) of incubation at 30°C after the addition of cycloheximide. Resulting cellular extracts were analyzed by Western immunoblotting. T+, protein extracts from Δ *ctk2* cells transformed with the CTK2-HA construct grown to an OD_{600} of 0.8.

matically reduced, indicating that the regulation of Ctk2p turnover is dependent on growth conditions. Concomitant with this process, we could not detect phosphorylated Ctk2p species, suggesting that either Ctk2p is not phosphorylated or Ctk2p-P is extremely rapidly dephosphorylated.

Taken together these results indicate a correlation between Ctk2p phosphorylation state and cyclin stability, suggesting that Ctk2p phosphorylation is a signal for its rapid degradation. This is reminiscent of previous data showing that phosphorylation of yeast cell cycle cyclins can trigger their selective degradation (28, 67, 68).

Ctk2p-P degradation is impaired in a mutant defective in proteasome activity. Eukaryotic cells contain two distinct systems for protein degradation: intravacuolar proteolysis (63) and a ubiquitin-mediated proteolysis that involves the proteasome and occurs in the cytoplasm as well as in the nucleus (18). Biochemical and genetic evidence indicates that the ubiquitin-proteasome pathway is involved in the degradation of abnormal proteins and regulatory proteins with naturally short half-lives such as cell cycle cyclins (20). Ctk2p turnover was not affected in the vacuolar protease-deficient *prl1 prb1 prc1 cps1* mutant strain (17) (data not shown). To establish whether Ctk2p was a substrate for the proteasome degradation pathway, we examined Ctk2p stability in the yeast *pre1 pre2* mutant strain, which is defective in two of the proteasome catalytic subunits (48). The CTK2-HA construct was introduced into *pre1 pre2* and wild-type isogenic cells. Cultures were subjected to a shift to the nonpermissive temperature (37°C) prior to addition of cycloheximide to impose the block in proteasome function. In wild-type cells, immunodetection of Ctk2p-P revealed a turnover of a few minutes, similar to what was previously observed (Fig. 4A). In contrast, in *pre1 pre2* cells, Ctk2p-P levels remained unchanged 10 min after cycloheximide addition (Fig. 4B). We note that before cycloheximide addition, the Ctk2p-P/Ctk2p ratio was different from that observed previously, indicating that it is dependent on genetic background and/or temperature. In conclusion, Ctk2p-P is dramatically stabilized in a mutant strain that exhibits defects in the activity of the proteasome, showing that its degradation is mediated by the 26S proteasome pathway.

If Ctk2p phosphorylation is a signal for its degradation, affecting this latter process might lead to the accumulation of phosphorylated species. Western blots analyses were performed with extracts made from *pre1 pre2* cells carrying the CTK2-HA construct, grown to the permissive temperature and shifted to the nonpermissive temperature (Fig. 4C). After incubation at the nonpermissive temperature, we observed a significant increase in Ctk2p-P steady-state levels correlated with a decrease in that of Ctk2p. This result shows that a block in Ctk2p destruction results in an important increase in Ctk2p-P/Ctk2p ratio, supporting the idea that phosphorylated Ctk2p




FIG. 4. Ctk2p turnover in cells that have impaired catalytic proteasome subunits. WCG4a (wild type [WT]; A) and isogenic WCG4-11/22a (*pre1 pre2*; B and C) cells transformed with the CTK2-HA construct were grown in SD medium to an OD_{600} of 0.8. For panels A and B, cultures were then shifted to the nonpermissive temperature (37°C) for 40 min prior to the addition of cycloheximide, and aliquots were taken at different times (minutes) of incubation at 37°C. (C) Cultures were shifted to the nonpermissive temperature for 1 or 3 h. Resulting cellular extracts were analyzed by Western immunoblotting.

species are indeed those that are rapidly degraded by the proteasome pathway.

Ctk2p-P degradation is an ubiquitin-mediated process. Although the 26S proteasome degrades an unknown number of proteins that are recognized without undergoing ubiquitination, the ubiquitin system constitutes the major targeting process leading to selective degradation (47). Ubiquitin is covalently attached to the protein substrate through an isopeptide bond in a multistep reaction, and repeated ubiquitination reactions culminate in attachment of a multiubiquitin chain that marks the target protein for rapid degradation by the 26S proteasome (20). Ubiquitin hydrolases act to remove ubiquitin from conjugated forms during either protein degradation or signalling. Cells disrupted for the *DOA4* gene encoding a deubiquitinating enzyme are disturbed for normal metabolism of ubiquitin and display a strong inhibition of the turnover of several soluble substrates of the ubiquitin pathway (45). To determine if Ctk2p degradation was mediated by the ubiquitin pathway, we studied Ctk2p turnover in cells disrupted for the *DOA4* gene. We compared the rates of Ctk2p turnover in Δ *doa4* and isogenic wild-type cells after inhibition of protein synthesis. As previously observed, Ctk2p-P turnover was very fast in wild-type cells, whereas the amounts of immunodetected Ctk2p-P in Δ *doa4* cells decreased only slightly after 15 min (Fig. 5A). Similar to what was observed in a proteasome mutant strain, Ctk2p-P degradation was strongly affected in Δ *doa4* mutant cells. Several studies have suggested that the




FIG. 5. Ctk2p degradation is a ubiquitin-dependent process. Cells were grown in SD medium to an OD_{600} of 0.8, and aliquots were taken at different times (minutes) of incubation at 30°C after the addition of cycloheximide. Resulting cellular extracts were analyzed by Western immunoblotting. (A) MHY501 (wild type [WT]) and isogenic MHY623 (Δ *doa4*) cells transformed with the CTK2-HA construct. (B) Δ *doa4* cells cotransformed with the CTK2-HA and YEp96 (wild-type ubiquitin [wt Ub]) plasmids. (C) MHY501 (wild type) cells cotransformed with the CTK2-HA and YEp110 (UbK48R) plasmids. In the right portions (+ Induction) of panels B and C, cells were grown for 5 h with $CuSO_4$ before they reached an OD_{600} of 0.8 in order to induce ubiquitin expression from the *CUP1* promoter.

amount of intracellular ubiquitin available for ubiquitination is limiting in Δ *doa4* cells (15, 45, 54). To find out whether an increase in ubiquitin levels could restore Ctk2p instability in the Δ *doa4* mutant strain, wild-type and Δ *doa4* cells were transformed with the multicopy plasmid YEp96, encoding a synthetic ubiquitin gene under the control of a *CUP1*-inducible promoter (10). $CuSO_4$ was added for 5 h to induce the *CUP1* promoter, and Ctk2p levels were monitored by immunodetection after cycloheximide addition. Overexpression of wild-type ubiquitin did not affect Ctk2p-P turnover in wild-type cells (data not shown). In contrast, overexpression of ubiquitin rescued Ctk2p-P turnover in Δ *doa4* cells (half-life, 5 to 10 min; Fig. 5B). In summary, we observed a significant stabilization of Ctk2p-P in Δ *doa4* cells. This effect was partially reversed by overproduction of wild-type ubiquitin, suggesting that an ubiquitin-mediated process is required for Ctk2p-P rapid degradation.

The targeting of substrates of the ubiquitin pathway to the proteasome is predominantly accomplished by the ligation of a polyubiquitin chain assembled through isopeptide bonds connecting the carboxyl-terminal Gly76 of one ubiquitin moiety to the ϵ -amino group of Lys48 of the adjacent ubiquitin molecule (5, 64). A modified ubiquitin carrying an arginine at position 48




FIG. 6. Ctk2p ubiquitin conjugates. W303-1B (wild type) cells cotransformed with plasmid YEp105 (Myc-tagged ubiquitin [Myc-Ub]) and either a control plasmid (–) or the CTK2-HA construct were grown in SD medium to an OD_{600} of 0.8 or 3 as indicated. $CuSO_4$ was (+) or was not (–) added overnight to the cultures in order to induce expression of the Myc-tagged ubiquitin. After immunoprecipitation with HA polyclonal antibodies, proteins were analyzed by Western immunoblotting with monoclonal Myc (upper panel) and monoclonal HA (lower panel) antibodies successively. Arrows and asterisks indicate bands corresponding to Ctk2p and nonspecific products, respectively.

instead of lysine (UbK48R) can still be conjugated to proteins but fails to function as an acceptor within the polyubiquitin chain, thus acting as a multiubiquitin chain terminator (2, 5, 13, 21, 52). If Lys48-linked multiubiquitination is a prerequisite for Ctk2p degradation, the presence of UbK48R should affect this process. The multicopy plasmid YEp110, carrying a gene encoding the variant UbK48R under the control of the *CUP1* promoter (21), was introduced into wild-type cells. Expression of UbK48R was induced for 5 h, and Ctk2p fate after cycloheximide addition was monitored by immunodetection. When UbK48R expression was induced, we could observe only a slight decrease in Ctk2p-P levels 15 min after cycloheximide addition, indicating a significant increase in Ctk2p-P stability (Fig. 5C). Since in all of these experiments cells also contained considerable amounts of wild-type ubiquitin, and because the mutant ubiquitin can be removed from the multiubiquitin chains (13), the inhibition of Ctk2p degradation by UbK48R was expected to be leaky. For that reason, we also analyzed the effect of UbK48R expression in Δ *doa4* cells that are thought to contain lower levels of free endogenous ubiquitin. Overproduction of UbK48R in Δ *doa4* cells resulted in a further and complete stabilization of Ctk2p-P (data not shown). In conclusion, Ctk2p-P destruction is substantially impaired by overexpression of UbK48R, demonstrating that this process requires the formation of Lys48-linked polyubiquitin chains.

One difficulty in establishing whether the degradation of a short-lived protein requires its conjugation to the ubiquitin system stems from the fact that depending on the relative rates of ubiquitination, deubiquitination, and degradation of the ubiquitin-containing protein, the steady-state levels of ubiquitinated species may range from negligible to readily detectable. Despite the fact that Ctk2p was readily observed by immunodetection, we did not observe any ubiquitinated forms. In an attempt to detect such species, Ctk2p was immunoprecipitated from wild-type cells overexpressing a Myc-tagged variant of ubiquitin from the *CUP1* promoter (11). Ctk2p species were further analyzed by Western immunoblotting (Fig. 6). Hybridization with Myc antibodies allowed detection of high-molecular-weight bands specific of the CTK2-HA construct only when Myc-ubiquitin expression was induced (Fig. 6, upper




FIG. 7. Ctk2p phosphorylation in $\Delta ctk1$ cells. $\Delta ctk1$ cells transformed with the CTK2-HA construct were grown in SD medium to an OD_{600} of 0.8. Aliquots were taken at different times (minutes) of incubation at 30°C after the addition of cycloheximide. Resulting cellular extracts were analyzed by Western immunoblotting. As a control (T+), protein extracts from $\Delta ctk2$ cells transformed with the CTK2-HA construct grown to an OD_{600} of 0.8 were loaded on the gel.

panel). Furthermore, these ubiquitin conjugates could not be observed when extracts were made from late exponential cells ($OD_{600} = 3$) (Fig. 6). Hybridization with HA antibodies (Fig. 6, lower panel) confirmed the presence of Ctk2p-ubiquitin conjugates only when phosphorylated Ctk2p forms were detected ($OD = 0.8$). On the contrary, we observed no ubiquitin conjugates when the cyclin was stable and its steady-state comprised only the unphosphorylated species ($OD = 3$). Altogether, these results demonstrate that Ctk2p is a substrate for the ubiquitin-proteasome pathway.

Ctk2p is phosphorylated in cells lacking the Ctk1p kinase.

Cell cycle cyclins have been shown to be rapidly degraded via the ubiquitin-proteasome pathway, and in several cases, mutagenesis analyses revealed that phosphorylation by their associated kinase provides a signal that promotes this process (28, 68). The fact that degradation of a cyclin is dependent on its cognate CDK subunit renders the cyclin-activated CDK activity self-limiting. To determine whether Ctk2p phosphorylation was dependent on its cognate kinase subunit, CTK2-HA construct was introduced into cells disrupted for the *CTK1* gene. Western blots analyses allowed detection of two bands corresponding to Ctk2p (Fig. 7), showing that the cyclin Ctk2p was phosphorylated in the absence of its activated kinase. Moreover, after cycloheximide addition, we observed a similar turnover for the phosphorylated form in $\Delta ctk1$ cells compared to wild-type cells (half-life, 5 min; Fig. 7 and data not shown). We note that Ctk2p abundance was lower in $\Delta ctk1$ mutant cells than in wild-type cells, consistent with Northern blots analyses showing that *CTK2* mRNA steady-state levels were substantially diminished in $\Delta ctk1$ cells (data not shown). Also, the Ctk2p-P/Ctk2p ratio was slightly lower in $\Delta ctk1$ cells than in wild-type cells, this effect being correlated with a significant stabilization of the unphosphorylated form. If Ctk2p phosphorylation is not as efficient in $\Delta ctk1$ cells as in wild-type cells, as a consequence one would expect to observe its stabilization. To obtain a better insight into the regulation of Ctk2p turnover in $\Delta ctk1$ cells, we analyzed Ctk2p expression in $\Delta ctk1$ cells grown to an OD of 3. As previously observed in wild-type cells (Fig. 3), Ctk2p was composed of only one band corresponding to the unphosphorylated form (data not shown). In conclusion, if there is a slight difference in Ctk2p turnover in $\Delta ctk1$ cells, it is probably nonspecifically affected due to the fact that Ctk2p is not an active protein, as it cannot be part of the CTDK-I complex.

We conclude that neither Ctk2p phosphorylation nor degradation is affected in $\Delta ctk1$ cells, showing that these processes require neither CTDK-I complex assembly nor its activity.

DISCUSSION

The C-type cyclin Ctk2p is phosphorylated in vivo. We have studied the expression of the yeast C-type cyclin Ctk2p, a cyclin subunit of the CTDK-I complex that is implicated in phosphorylation of the RNA polymerase II CTD. We show that steady-state levels of Ctk2p in pseudo-wild-type exponential-phase cells (a functional tagged version of the cyclin was expressed from its cognate promoter carried by a single-copy plasmid introduced into $\Delta ctk2$ cells) are composed of two forms, one a phosphorylated form. This is the first description of a C-type cyclin phosphorylation. Examination of Ctk2p protein sequence did not reveal the presence of a strong PEST-rich motif, and as yet no phosphorylated residues have been identified. One difficulty in studying cell cycle cyclins at the protein levels is that yeast cells contain very little of these proteins. In contrast, phosphorylated as well as nonphosphorylated species of Ctk2p are relatively abundant during exponential growth. This striking feature might reflect a role for Ctk2p in regulating transcription rather than cell cycle progression. Indeed, cell cycle CDKs are known to interact sequentially with several distinct cyclins whose abundance fluctuates during the cell cycle (43). Yeast CDKs activated by C-type cyclins seem to be an exception from this principle, as only one cyclin has been characterized per kinase subunit, indicating clearly that different features govern regulation of CDKs that are implicated in transcription control.

That Ctk2p steady state is composed of nonphosphorylated as well as phosphorylated species raises the question of which species are functional. Because in the absence of Ctk2p-P the cyclin is stable, it is likely that the CTDK-I complex is active. Indeed, under growth conditions where Ctk2p steady state is mainly composed of the unphosphorylated form, preliminary experiments suggest that the CTDK-I complex is active (unpublished results). Several studies have shown that cell cycle cyclin phosphorylation is required for the control of their degradation but not for their capacity to activate their associated kinase (9, 28). It is thus likely that, similar to the case for cell cycle cyclins, Ctk2p phosphorylation is not required for its function.

Ctk2p degradation is mediated by the ubiquitin-proteasome pathway. We have blocked cytoplasmic translation with cycloheximide to study Ctk2p stability. We show that under these conditions, Ctk2p is a moderately unstable protein (half-life, 60 min) whereas its phosphorylated form is extremely unstable (half-life, 5 min). Because C-type cyclin expression may vary upon diverse stress conditions, pulse-chase experiments would be required to determine whether Ctk2p turnover is affected by cycloheximide.

In eukaryotic cells, protein degradation is mediated by two distinct systems: the nonspecific intravacuolar proteolysis system, which is rather implicated in the stress response (63); and the proteasome ubiquitin-mediated pathway, which has been implicated in specific degradation of abnormal proteins as well as short-lived proteins (18). Ctk2p turnover is not affected in cells deficient in the major vacuolar peptidases (data not shown), whereas it is markedly affected in a mutant strain deficient for two of the proteasome catalytic subunits (*pre1 pre2*) (48), indicating that Ctk2p destruction is mediated by the proteasome pathway. Although other cases have been described, targeting to the proteasome usually requires attachment of ubiquitin chains to substrate proteins (47). These chains are highly dynamic, with rapid addition or removal of ubiquitin by deubiquitinating enzymes. Ctk2p degradation is substantially impaired in cells lacking the *DOA4* gene, which encodes one of the 16 deubiquitinating enzymes characterized

in yeast (20, 45). This impairment is partially rescued by overexpression of wild-type ubiquitin, confirming previous observations indicating that levels of free ubiquitin are limiting in $\Delta doa4$ cells (15, 45, 54). Finally, we could observe Ctk2p-ubiquitin conjugates by using tagged ubiquitin. As expected, these forms were detected under conditions where Ctk2p displays a short turnover but not under conditions where Ctk2p is stable. Moreover, consistent with a function of the ubiquitin system in Ctk2p degradation, expression of a mutant ubiquitin (UbK48R) that prevents the formation of polyubiquitin chains (2, 13, 21, 52) generated an increase in Ctk2p stability. Taken together, these results demonstrate the role of K48-linked polyubiquitination in the rapid degradation of Ctk2p by the proteasome.

The yeast C-type cyclin Ume3p has also been reported to be down-regulated but there was no evidence for the involvement of the ubiquitin pathway in its degradation (6). The authors suggested that Ume3p might be destroyed through a mechanism different from those described for other cyclins. On the contrary, we show that similar to the case for other short-lived proteins, rapid destruction of Ctk2p is mediated by the specific ubiquitin-proteasome pathway.

Control of Ctk2p turnover. Patturajan et al. (46) reported recently that the pattern of CTD phosphorylation in yeast varies in response to growth conditions and environmental stress. Among the three C-type cyclins identified in yeast, Ume3p and Ctk2p are associated with nonessential CTD kinases that are implicated in transcription regulation. Ume3p is rapidly destroyed when cells enter the meiotic pathway or are exposed to heat shock (6). Ctk2p is expected to be stabilized whenever CTDK-I kinase activity is required. In this report, we show that Ctk2p is very stable in late-exponential-phase cells, demonstrating that this regulatory protein is not constitutively short-lived.

Several lines of evidence suggest that Ctk2p phosphorylation is a signal for its rapid destruction: (i) as discussed above, Ctk2p phosphorylation does not seem to be required for CTDK-I function, indicating that this event must be implicated in another process; (ii) in late-exponential-phase cells, Ctk2p stabilization is, as expected, correlated with the absence of ubiquitin conjugates but also with the absence of Ctk2p phosphorylation; (iii) Ctk2p-P is extremely unstable in wild-type cells, whereas it is very stable in a proteasome mutant strain; (iv) finally, we observe an important increase in the Ctk2p-P/Ctk2p ratio when the cyclin destruction is blocked. Taken together, these data strongly suggest that similar to the case for G₁ cyclins, Ctk2p degradation is induced by phosphorylation. It has been shown that the degradation of cell cycle cyclins is dependent on their associated kinase activity (7, 28, 68). Once the cyclin is expressed, it activates its kinase, which in return phosphorylates its cyclin, a signal inducing its rapid and specific ubiquitin-mediated degradation through the proteasome pathway. Unexpectedly, neither phosphorylation nor turnover of Ctk2p is significantly affected in cells disrupted for the gene encoding the kinase subunit of the CTDK-I complex. We cannot exclude the possibility that the Ctk1p kinase plays a role in Ctk2p phosphorylation in wild-type cells; however, if such phosphorylation events take place, they are unlikely to play a role in the control of Ctk2p turnover.

Similarly, it has been shown that the rapid degradation of Ume3p was not dependent on the presence of the CDK that it activates (6). Although Ume3p phosphorylation has not been reported, it is worth noting that integrity of the Ume3p cyclin box, i.e., its kinase binding domain (25, 32), is required for its breakdown (6). This peculiar feature raises the interesting possibility that the Ume3p cyclin box is required for an interaction

with another CDK. It thus appears that unlike turnover of cell cycle cyclins, turnover of C-type cyclins is not controlled by their cognate kinases, and it will be important to determine whether Ctk2p phosphorylation is dependent on another CDK that could be activated by CTD kinase cyclins or could phosphorylate monomeric C-type cyclins.

In conclusion, we show in this report that similar to expression of cell cycle cyclins, Ctk2p expression is regulated by rapid proteolysis mediated by the ubiquitin-proteasome pathway. However, it is apparent that regulation of the turnover of C-type cyclins exhibits specific features that are likely to be the signature of their function in transcription control, as indeed another kinase activity can phosphorylate Ctk2p, thereby probably regulating its turnover.

ACKNOWLEDGMENTS

We are very grateful to C. Jacq for scientific and financial support during this work. We thank M. Hochstrasser and D. Wolf for providing strains. Special thanks are due to R. Haguenaer-Tsapis for stimulating discussions and critical reading of the manuscript. We also thank members of C. Jacq's laboratory for many helpful discussions and to S. Moore for helpful comments and for proofreading the manuscript.

G.H. was supported by a French Ministère de la Recherche et des Technologies fellowship.

REFERENCES

- Balciunas, D., and H. Ronne. 1995. Three subunits of the RNA polymerase II mediator complex are involved in glucose repression. *Nucleic Acids Res.* **23**:4421-4425.
- Biederer, T., C. Volkwein, and T. Sommer. 1996. Degradation of subunits of the Sec61p complex, an integral component of the ER membrane, by the ubiquitin-proteasome pathway. *EMBO J.* **15**:2069-2076.
- Bonneaud, N., O. Ozier-Kalogeropoulos, G. Li, M. Labouesse, L. Minvielle-Sebastia, and F. Lacroute. 1991. A family of low and high copy replicative, integrative and single-stranded *S. cerevisiae/E. coli* shuttle vectors. *Yeast* **7**:609-615.
- Chardin, P., J. H. Camomis, N. W. Gale, L. Van Aelst, J. Schlessinger, M. Wigler, and D. Bar-Sagi. 1993. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to Grb2. *Science* **260**:1338-1343.
- Chau, V., J. W. Tobias, A. Bachmair, D. Marriott, D. J. Ecker, D. K. Gonda, and A. Varshavsky. 1989. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. *Science* **243**:1576-1583.
- Cooper, K. F., M. J. Mallory, J. B. Smith, and R. Strich. 1997. Stress and developmental regulation of the yeast C-type cyclin Ume3p (Srb11p/Ssn8p). *EMBO J.* **16**:4665-4675.
- Cross, F. R., and C. M. Blake. 1993. The yeast Cln3 protein is an unstable activator of Cdc28. *Mol. Cell. Biol.* **13**:3266-3271.
- Dahmus, M. E. 1996. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. *J. Biol. Chem.* **271**:19009-19012.
- Deshaies, R. J., V. Chau, and M. Kirschner. 1995. Ubiquitination of the G₁ cyclin Cln2p by a Cdc34p-dependent pathway. *EMBO J.* **14**:303-312.
- Ecker, D. J., M. I. Khan, J. Marsh, T. R. Butt, and S. T. Crooke. 1987. Chemical synthesis and expression of a cassette adapted ubiquitin gene. *J. Biol. Chem.* **262**:3524-3527.
- Ellison, M. J., and M. Hochstrasser. 1991. Epitope-tagged ubiquitin. *J. Biol. Chem.* **266**:21150-21157.
- Faye, G., M. Simon, J.-G. Valay, D. Fesquet, and C. Facca. 1997. Rig2, a RING finger protein that interacts with the Kin28/Cc11 CTD kinase in yeast. *Mol. Gen. Genet.* **255**:460-466.
- Finley, D., S. Sadis, B. P. Monia, P. Boucher, D. J. Ecker, S. T. Crooke, and V. Chau. 1994. Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant. *Mol. Cell. Biol.* **14**:5501-5509.
- Furnari, B. A., P. Russell, and J. Leatherwood. 1997. *pch1⁺*, a second essential C-type cyclin gene in *Schizosaccharomyces pombe*. *J. Biol. Chem.* **272**:12100-12106.
- Galan, J. M., and R. Haguenaer-Tsapis. 1997. Ubiquitin Lys63 is involved in ubiquitination of a yeast plasma membrane protein. *EMBO J.* **16**:5847-5854.
- Glotzer, M., A. W. Murray, and M. W. Kirschner. 1991. Cyclin is degraded by the ubiquitin pathway. *Nature* **349**:132-138.
- Heinmeyer, W., J. Kleinschmidt, J. Saidowsky, C. Escher, and D. Wolf. 1991. Proteinase yscE, the yeast proteasome/multicatalytic-multifunctional proteinase: mutants unravel its function in stress induced proteolysis and uncover its necessity for cell survival. *EMBO J.* **10**:555-562.
- Hilt, W., and D. H. Wolf. 1996. Proteasomes: destruction as a programme. *Trends Biochem. Sci.* **21**:96-102.

19. Hochstrasser, M. 1995. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. *Curr. Opin. Cell Biol.* **7**:215–223.
20. Hochstrasser, M. 1996. Ubiquitin-dependent protein degradation. *Annu. Rev. Genet.* **30**:405–439.
21. Hochstrasser, M., M. J. Ellison, V. Chau, and A. Varshavsky. 1991. The short-lived MAT α 2 transcriptional regulator is ubiquitinated *in vivo*. *Proc. Natl. Acad. Sci. USA* **88**:4606–4610.
22. Ito, H., Y. Fukuda, K. Murata, and A. Kumura. 1983. Transformation of intact yeast cells treated with alkali cations. *J. Bacteriol.* **153**:163–168.
23. King, R. W., R. J. Deshaies, J.-M. Peters, and M. W. Kirschner. 1996. How proteolysis drives the cell cycle. *Science* **274**:1652–1659.
24. King, R. W., M. Glotzer, and M. W. Kirschner. 1996. Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates. *Mol. Cell. Biol.* **7**:1343–1357.
25. Kobayashi, H., E. Stewart, R. Poon, J. P. Adamczewski, J. Gannon, and T. Hunt. 1992. Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits. *Mol. Biol. Cell* **3**:1279–1294.
26. Kuchin, S., and M. Carlson. 1998. Functional relationships of Srb10-Srb11 kinase, carboxy-terminal domain kinase CTDK-I, and transcriptional corepressor Ssn6-Tup1. *Mol. Cell. Biol.* **18**:1163–1171.
27. Kuchin, S., P. Yeghiayan, and M. Carlson. 1995. Cyclin-dependent protein kinase and cyclin homologs SSN3 and SSN8 contribute to transcriptional control in yeast. *Proc. Natl. Acad. Sci. USA* **92**:4006–4010.
28. Lancker, S., M. H. Valdivieso, and C. Wittenberg. 1996. Rapid degradation of the G₁ cyclin Cln2 induced by CDK-dependent phosphorylation. *Science* **271**:1597–1601.
29. Lee, J. M., and A. L. Greenleaf. 1989. A protein kinase that phosphorylates the C-terminal repeat domain of the largest subunit of RNA polymerase II. *Proc. Natl. Acad. Sci. USA* **86**:3624–3628.
30. Lee, J. M., and A. L. Greenleaf. 1991. CTD kinase large subunit is encoded by *CTK1*, a gene required for normal growth of *Saccharomyces cerevisiae*. *Gene Expr.* **1**:149–167.
31. Lee, J. M., and A. L. Greenleaf. 1997. Modulation of RNA polymerase II elongation efficiency by C-terminal heptapeptide repeat domain kinase I. *J. Biol. Chem.* **272**:10990–10993.
32. Lees, E. M., and E. Harlow. 1993. Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. *Mol. Cell. Biol.* **13**:1194–1201.
33. Léopold, P., and P. H. O'Farrell. 1991. An evolutionarily conserved cyclin homolog from *Drosophila* rescues yeast deficient in G1 cyclins. *Cell* **66**:1207–1216.
34. Lew, D. J., V. Dulic, and S. I. Reed. 1991. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. *Cell* **66**:1197–1206.
35. Liao, S.-M., J. Zhang, D. A. Jeffery, A. J. Koleske, C. M. Thompson, D. M. Chao, M. Viljoen, H. J. J. van Vuuren, and R. A. Young. 1995. A kinase-cyclin pair in the RNA polymerase II holoenzyme. *Nature* **374**:193–196.
36. Liu, Z.-J., T. Ueda, T. Miyazaki, N. Tanaka, S. Mine, Y. Tanaka, T. Taniguchi, H. Yamamura, and Y. Minami. 1998. A critical role for cyclin C in promotion of the hematopoietic cell cycle by cooperation with c-Myc. *Mol. Cell. Biol.* **18**:3445–3454.
37. Lu, H., L. Zawal, L. Fisher, J.-M. Egly, and D. Reinberg. 1992. Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II. *Nature* **358**:641–645.
38. Marshall, N. F., and D. H. Price. 1995. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. *J. Biol. Chem.* **270**:12335–12338.
39. Molz, L., and D. Beach. 1993. Characterization of the fission yeast *mcs2* cyclin and its associated protein kinase activity. *EMBO J.* **12**:1723–1732.
40. Morgan, D. O. 1995. Principles of CDK regulation. *Nature* **374**:131–134.
41. Morgan, D. O. 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. *Annu. Rev. Cell Dev. Biol.* **13**:261–291.
42. Murray, A. W., M. J. Solomon, and M. W. Kirschner. 1989. The role of cyclin synthesis and degradation in the control of maturation promoting factor activity. *Nature* **339**:280–286.
43. Nasmyth, K. 1993. Control of the yeast cell cycle by the Cdc28 protein kinase. *Curr. Opin. Cell Biol.* **5**:166–179.
44. Nigg, E. A. 1996. Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? *Curr. Opin. Cell Biol.* **8**:312–317.
45. Papa, F. R., and M. Hochstrasser. 1993. The yeast *DOA4* gene encodes a deubiquitinating enzyme related to a product of the human *tre-2* oncogene. *Nature* **366**:313–319.
46. Patturajan, M., R. J. Schulte, B. M. Sefton, R. Berezney, M. Vincent, O. Bensaude, S. L. Warren, and J. L. Corden. 1998. Growth-related changes in phosphorylation of yeast RNA polymerase II. *J. Biol. Chem.* **273**:4689–4694.
47. Pickart, C. M. 1997. Targeting of substrates to the 26S proteasome. *FASEB J.* **11**:1055–1066.
48. Richter-Ruoff, B., D. H. Wolf, and M. Hochstrasser. 1994. Degradation of the yeast MAT alpha 2 transcriptional regulator is mediated by the proteasome. *FEBS Lett.* **354**:50–52.
49. Rogers, S., R. Wells, and M. Rechsteiner. 1986. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. *Science* **234**:364–368.
50. Rothstein, R. J. 1983. One step gene disruption in yeast. *Methods Enzymol.* **101**:202–211.
51. Salama, S. R., K. B. Hendricks, and J. Thorner. 1994. G1 cyclin degradation: the PEST motif of yeast Cln2 is necessary, but not sufficient, for rapid protein turnover. *Mol. Cell. Biol.* **14**:7953–7966.
52. Schork, S. M., M. Thumm, and D. H. Wolf. 1995. Catabolite inactivation of Fructose-1,6-bisphosphatase of *Saccharomyces cerevisiae*. *J. Biol. Chem.* **270**:26446–26450.
53. Seufert, W., B. Futcher, and S. Jentsch. 1995. Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins. *Nature* **373**:78–81.
54. Singer, J. D., B. M. Manning, and T. Formosa. 1996. Coordinating DNA replication to produce one copy of the genome requires genes that act in ubiquitin metabolism. *Mol. Cell. Biol.* **16**:1356–1366.
55. Song, W., and M. Carlson. 1998. Srb/mediator proteins interact functionally and physically with transcriptional repressor Sfl1. *EMBO J.* **17**:5757–5765.
56. Sterner, D. E., J. Moon Lee, S. E. Hardin, and A. L. Greenleaf. 1995. The yeast carboxyl-terminal repeat domain kinase CTDK-I is a divergent cyclin-cyclin-dependent kinase complex. *Mol. Cell. Biol.* **15**:5716–5724.
57. Surosky, R. T., R. Strich, and R. E. Esposito. 1994. The yeast *UME5* gene regulates the stability of meiotic mRNAs in response to glucose. *Mol. Cell. Biol.* **14**:3446–3458.
58. Svejstrup, J. Q., P. Vichi, and J.-M. Egly. 1996. The multiple roles of transcription/repair factor TFIIH. *Trends Biochem. Sci.* **21**:346–350.
59. Tassan, J.-P., M. Jaquenoud, P. Léopold, S. J. Schultz, and E. A. Nigg. 1995. Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. *Proc. Natl. Acad. Sci. USA* **92**:8871–8875.
60. Tyers, M., G. Tokiwa, R. Nash, and B. Futcher. 1992. The Cln3-Cdc28 kinase complex of *S. cerevisiae* is regulated by proteolysis and phosphorylation. *EMBO J.* **11**:1773–1784.
61. Valay, J.-G., M.-F. Dubois, O. Bensaude, and G. Faye. 1996. Ccl1, a cyclin associated with protein kinase Kin28, controls the phosphorylation of RNA polymerase II largest subunit and mRNA transcription. *C. R. Acad. Sci. (Paris)* **319**:183–189.
62. Valay, J.-G., M. Simon, M.-F. Dubois, O. Bensaude, C. Facca, and G. Faye. 1995. The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD. *J. Mol. Biol.* **249**:535–544.
63. Van Den Hazel, H. B., M. C. Kielland-Brandt, and J. R. Winther. 1996. Review: biosynthesis and function of yeast vacuolar proteases. *Yeast* **12**:1–16.
64. Van Nocker, S., and R. D. Vierstra. 1993. Multiubiquitin chains linked through lysine 48 are abundant *in vivo* and are competent intermediates in the ubiquitin proteolytic pathway. *J. Biol. Chem.* **268**:24766–24773.
65. Wahi, M., and A. D. Johnson. 1995. Identification of genes required for α 2 repression in *Saccharomyces cerevisiae*. *Genetics* **140**:79–90.
66. Wei, P., M. E. Garber, S.-M. Fang, W. H. Fischer, and K. A. Jones. 1998. A novel Cdk9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell* **92**:451–462.
67. Willems, A. R., S. Lancker, E. E. Patton, K. L. Craig, T. F. Nason, N. Mathias, R. Kobayashi, C. Wittenberg, and M. Tyers. 1996. Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway. *Cell* **86**:453–463.
68. Yaglom, J., M. H. K. Linskens, S. Sadis, D. M. Rubin, B. Futcher, and D. Finley. 1995. p34^{Cdc28}-mediated control of Cln3 cyclin degradation. *Mol. Cell. Biol.* **15**:731–741.
69. Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathews, and D. H. Price. 1997. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation *in vitro*. *Genes Dev.* **11**:2622–2632.